BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Bone cancer AND KMT2A, TRX1, 4297, MLL, ENSG00000118058, MLL/GAS7, HTRX1, HRX, ALL-1, MLL1A, CXXC7
412 results:

  • 1. A rare kmt2a::CBL transcript in an acute monoblastic leukemia patient with an unfavorable outcome.
    Yu J; Song F; Zhang M; Xiao P; Feng J; Hong R; Hu Y; Huang H; Wei G
    Mol Biol Rep; 2024 Apr; 51(1):561. PubMed ID: 38643442
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Impact of mll::AF9 Gene Rearrangement on Survival of Acute Myeloid Leukaemia Patients: An Insight into Pakistani Population.
    Tariq M; Shahab S; Saeed JR; Hussain Z; Zaidi U; Farzana T; Ahmad S
    J Coll Physicians Surg Pak; 2024 Apr; 34(4):424-428. PubMed ID: 38576284
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Structural variants involving mllT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia.
    Abla O; Ries RE; Triche T; Gerbing RB; Hirsch B; Raimondi S; Cooper T; Farrar JE; Buteyn N; Harmon LM; Wen H; Deshpande AJ; Kolb EA; Gamis AS; Aplenc R; Alonzo T; Meshinchi S
    Blood Adv; 2024 Apr; 8(8):2005-2017. PubMed ID: 38306602
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Sclerosing Epithelioid Fibrosarcoma.
    Warmke LM; Yu W; Meis JM
    Surg Pathol Clin; 2024 Mar; 17(1):119-139. PubMed ID: 38278601
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Iron overload promotes the progression of mll-AF9 induced acute myeloid leukemia by upregulation of FOS.
    Yang F; Cui X; Wang H; Zhang D; Luo S; Li Y; Dai Y; Yang D; Zhang X; Wang L; Zheng G; Zhang X
    Cancer Lett; 2024 Feb; 583():216652. PubMed ID: 38242196
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer.
    Zhang H; Huang C; Gordon J; Yu S; Morton G; Childers W; Abou-Gharbia M; Zhang Y; Jelinek J; Issa JJ
    Clin Epigenetics; 2024 Jan; 16(1):3. PubMed ID: 38172923
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study.
    Conter V; Valsecchi MG; Cario G; Zimmermann M; Attarbaschi A; Stary J; Niggli F; Dalla Pozza L; Elitzur S; Silvestri D; Locatelli F; Möricke A; Engstler G; Smisek P; Bodmer N; Barbaric D; Izraeli S; Rizzari C; Boos J; Buldini B; Zucchetti M; von Stackelberg A; Matteo C; Lehrnbecher T; Lanvers-Kaminsky C; Cazzaniga G; Gruhn B; Biondi A; Schrappe M
    J Clin Oncol; 2024 Mar; 42(8):915-926. PubMed ID: 38096462
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Deletion of Mettl3 in mesenchymal stem cells promotes acute myeloid leukemia resistance to chemotherapy.
    Liao X; Cai D; Liu J; Hu H; You R; Pan Z; Chen S; Xu K; Dai W; Zhang S; Lin X; Huang H
    Cell Death Dis; 2023 Dec; 14(12):796. PubMed ID: 38052820
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Intravital Microscopy to Study the Effect of Matrix Metalloproteinase Inhibition on Acute Myeloid Leukemia Cell Migration in the bone Marrow.
    Tissot FS; Gonzalez-Anton S; Lo Celso C
    Methods Mol Biol; 2024; 2747():211-227. PubMed ID: 38038943
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals RNA N6-methyladenosine modification associated with prognosis and drug resistance in acute myeloid leukemia.
    Li Z; Liu X; Wang L; Zhao H; Wang S; Yu G; Wu D; Chu J; Han J
    Front Immunol; 2023; 14():1281687. PubMed ID: 38022588
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Cutaneous Manifestations of Myeloid Neoplasms Exhibit Broad and Divergent Morphologic and Immunophenotypic Features but Share Ancestral Clonal Mutations With bone Marrow.
    Sadigh S; DeAngelo DJ; Garcia JS; Hasserjian RP; Hergott CB; Lane AA; Lovitch SB; Lucas F; Luskin MR; Morgan EA; Pinkus GS; Pozdnyakova O; Rodig SJ; Shanmugam V; Tsai HK; Winer ES; Zemmour D; Kim AS
    Mod Pathol; 2024 Jan; 37(1):100352. PubMed ID: 37839675
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Practice Preferences for Consolidative Hematopoietic Stem Cell Transplantation Following Tisagenlecleucel in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia.
    McNerney KO; Moskop A; Winestone LE; Baggott C; Talano JA; Schiff D; Rossoff J; Modi A; Verneris MR; Laetsch TW; Schultz L
    Transplant Cell Ther; 2024 Jan; 30(1):75.e1-75.e11. PubMed ID: 37816472
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Distinct and targetable role of calcium-sensing receptor in leukaemia.
    Pereira RS; Kumar R; Cais A; Paulini L; Kahler A; Bravo J; Minciacchi VR; Krack T; Kowarz E; Zanetti C; Godavarthy PS; Hoeller F; Llavona P; Stark T; Tascher G; Nowak D; Meduri E; Huntly BJP; Münch C; Pampaloni F; Marschalek R; Krause DS
    Nat Commun; 2023 Oct; 14(1):6242. PubMed ID: 37802982
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Mechanisms of Secondary Leukemia Development Caused by Treatment with DNA Topoisomerase Inhibitors.
    Lomov NA; Viushkov VS; Rubtsov MA
    Biochemistry (Mosc); 2023 Jul; 88(7):892-911. PubMed ID: 37751862
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Constitutively Synergistic Multiagent Drug Formulations Targeting MERTK, FLT3, and BCL-2 for Treatment of AML.
    Kelvin JM; Jain J; Thapa A; Qui M; Birnbaum LA; Moore SG; Zecca H; Summers RJ; Switchenko JM; Costanza E; Uricoli B; Wang X; Jui NT; Fu H; Du Y; DeRyckere D; Graham DK; Dreaden EC
    Pharm Res; 2023 Sep; 40(9):2133-2146. PubMed ID: 37704893
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Repression of TRIM13 by chromatin assembly factor CHAF1B is critical for AML development.
    Dean ST; Ishikawa C; Zhu X; Walulik S; Nixon T; Jordan JK; Henderson S; Wyder M; Salomonis N; Wunderlich M; Greis KD; Starczynowski DT; Volk AG
    Blood Adv; 2023 Sep; 7(17):4822-4837. PubMed ID: 37205848
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications.
    Darzentas F; Szczepanowski M; Kotrová M; Hartmann A; Beder T; Gökbuget N; Schwartz S; Bastian L; Baldus CD; Pál K; Darzentas N; Brüggemann M
    Front Immunol; 2023; 14():1125017. PubMed ID: 37143651
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Clinical and Molecular Characteristics of Patients with Mixed Phenotype Acute Leukemia.
    Kandeel EZ; Hassan NM; El Ashry MS
    Asian Pac J Cancer Prev; 2023 Apr; 24(4):1217-1223. PubMed ID: 37116143
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Myeloid sarcoma in a newborn: A rare manifestation of congenital acute myeloid leukemia.
    Mullen B; Sabet K; Jacobs S; Calleroz AT; Habeshian KA; Cheng J
    Pediatr Dermatol; 2023; 40(4):751-752. PubMed ID: 37029447
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. The kmt2a recombinome of acute leukemias in 2023.
    Meyer C; Larghero P; Almeida Lopes B; Burmeister T; Gröger D; Sutton R; Venn NC; Cazzaniga G; Corral Abascal L; Tsaur G; Fechina L; Emerenciano M; Pombo-de-Oliveira MS; Lund-Aho T; Lundán T; Montonen M; Juvonen V; Zuna J; Trka J; Ballerini P; Lapillonne H; Van der Velden VHJ; Sonneveld E; Delabesse E; de Matos RRC; Silva MLM; Bomken S; Katsibardi K; Keernik M; Grardel N; Mason J; Price R; Kim J; Eckert C; Lo Nigro L; Bueno C; Menendez P; Zur Stadt U; Gameiro P; Sedék L; Szczepański T; Bidet A; Marcu V; Shichrur K; Izraeli S; Madsen HO; Schäfer BW; Kubetzko S; Kim R; Clappier E; Trautmann H; Brüggemann M; Archer P; Hancock J; Alten J; Möricke A; Stanulla M; Lentes J; Bergmann AK; Strehl S; Köhrer S; Nebral K; Dworzak MN; Haas OA; Arfeuille C; Caye-Eude A; Cavé H; Marschalek R
    Leukemia; 2023 May; 37(5):988-1005. PubMed ID: 37019990
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 21.